Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease

Respir Med. 2006 Jun;100(6):1110-6. doi: 10.1016/j.rmed.2005.09.019. Epub 2005 Oct 19.

Abstract

Background: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients.

Methods: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with 20 pack-years of smoking, FEV(1)/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV(1)<80%. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV(1)-100)/pack-years.

Results: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P=0.0003) and had more pack-years of smoking (57 vs. 43, P=0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans (SI=-1.02% vs. -1.34%, P=0.007) and men less than women (SI=-0.98% vs. -1.21%, P=0.001). Caucasian males appeared relatively protected from tobacco smoke (SI=-0.93%), while African-American women appeared most susceptible (SI=-1.42%).

Conclusions: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.

Publication types

  • Comparative Study

MeSH terms

  • African Americans
  • Analysis of Variance
  • Bronchodilator Agents / therapeutic use
  • Chi-Square Distribution
  • Cross-Sectional Studies
  • Disease Susceptibility
  • European Continental Ancestry Group
  • Female
  • Forced Expiratory Volume
  • Humans
  • Male
  • Patient Selection
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / ethnology*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Sex Factors*
  • Smoking / adverse effects*
  • Treatment Outcome

Substances

  • Bronchodilator Agents